Notably, the targeted STING inhibitor ISD017 has shown effectiveness in reducing glomerulonephritis in Fcgr2b-deficient mice, as well as diminishing ISG responses in peripheral blood mononuclear cells (PBMC) from SLE patients25. This evidence concerns the gene STING1 and glomerulonephritis.